Navigation Links
Today's Research on Celsion, Zogenix, Actavis, and Avanir Pharma
Date:4/10/2013

LONDON, April 10, 2013 /PRNewswire/ --

One of the major trends to emerge in the healthcare industry in the last year has been the expiration of patents on several blockbuster drugs. This had led to increasing competition from generic drug companies such as Actavis Inc. (NYSE: ACT) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR). For major drug manufacturers such as Zogenix Inc. (NASDAQ: ZGNX), the key will be to continue to boost their product pipeline. Major drug manufacturers are also likely to collaborate with biotechnology companies such as Celsion Corporation (NASDAQ: CLSN) that are developing or have developed potential blockbuster drugs. On Tuesday, healthcare stocks ended on a mixed note even as the broad market posted significant gains. StockCall professionals have completed their technical analysis on CLSN, ZGNX, ACT, and AVNR and these free reports are accessible by registering at

http://www.stockcall.com/research  

Shares of Celsion Corporation edged higher yesterday; however, the gains were limited. The stock touched an intra-day high of $1 before finishing the day 0.41% higher at $0.974 on volume of 523,658. Despite the gains on Tuesday, Celsion's shares have fallen more than 4.50% in the last three trading sessions. Year-to-date, the stock has lost more than 88% of its value. Most of the losses came in February when the stock saw a steep decline. In the last one month, shares of CLSN have traded sideways, struggling to break through $1 level. Sign up for the free technical research on CLSN at

http://www.StockCall.com/CLSN041013.pdf

Shares of Zogenix Inc. saw a sharp decline in trading on Tuesday. The stock ended the day 2.52% lower at $1.55 on volume of 515,540. The stock has now fallen more than 13.40% in the last three trading sessions. The major drug maker's shares have fallen sharply after the stock failed to break through $2 resistance level. The stock recently slipped below $1.60 support level, and also its 50-day moving average. This suggests that market sentiment is currently bearish on the stock. The downbeat trend is further confirmed by the stock's MACD chart. Be sure to read our latest technical research on ZGNX by registering at

http://www.StockCall.com/ZGNX041013.pdf

Actavis Inc.'s shares ended marginally lower on Tuesday. The stock touched a 52-week high of $98.46 earlier in the day; however, it failed to hold onto its gains. Actavis' shares ended the day 0.66% lower at $97.71 on volume of 1.10 million. Despite the losses yesterday, the generic drug maker's shares are still up nearly 2% in the last three trading sessions. The stock has had an excellent run so far in 2013, gaining more than 13.60%. The company's shares have seen a series of highs since last month, which is a bullish signal. Sign up and read the complimentary report on ACT at

http://www.StockCall.com/ACT041013.pdf

Avanir Pharmaceuticals Inc.'s shares were among the major gainers in the healthcare sector on Tuesday. The stock closed 2.65% higher at $2.71 on volume of 594,199 after touching an intra-day high of $2.77. Avanir's shares are currently trading more than 33% below their 52-week high. The stock bounced back yesterday after seeing a series of lows in the past two weeks. Shares of this generic drug maker are still trading well below their 50-day and 200-day moving averages, which is a bearish signal. The negative trend is further confirmed by the stock's MACD chart.  The free report on AVNR can be downloaded by signing up now at

http://www.StockCall.com/AVNR041013.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
2. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
3. St. Johns Research Institute Honored by Waters Center of Innovation Program
4. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
5. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
6. Manchester leads the way in graphene membrane research
7. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
8. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
9. Solution Styrene Butadiene Rubber (S-SBR) Market is Expected to Reach USD 3.2 Billion in 2018: Transparency Market Research
10. Elsevier and the Belarus Ministry of Education Honor Researchers with Scopus Awards
11. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):